Barcelona

• Study of U3-1402 in subjects with non-small cell lung cancer Ended recruitment
  2024-511205-33-00 3 2020-05-18 METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER
• Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed … Ended recruitment
  2023-510537-28-00 5 2020-05-15 Multiple Myeloma
• A study for subjects after organ or cell transplantation after failure of prior treatment Ended recruitment
  2024-516622-57-00 5 2020-05-06 Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Dise
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Ended recruitment
  2023-505042-25-00 5 2020-05-05 Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
• A Phase 1/2 Study on the effects of the LOXO-292 (study drug) in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tu … Ended recruitment
  2023-507703-63-00 9 2020-05-04 Pediatric Patients with Advanced RET-Altered Solid or Primary Central
• Utility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutations Ended recruitment
  2024-511317-38-00 4 2020-05-04 ALK+ non-small cell lung cancer
• A trial to learn how camizestrant (AZD9833) works compared to fulvestrant and how safe it is in women with advanced breast cancer who have g … Ended recruitment
  2023-504974-40-00 4 2020-04-24 Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer
• A study of NY-ESO-1 T-cells (GSK3377794) in synovial sarcoma and myxoid/round cell liposarcoma patients Ended recruitment
  2024-513032-14-00 4 2020-04-21 Synovial sarcoma and Myxoid/Round Cell Liposarcoma (MRCLS)
• Phase 1/2 Study of CLN-081 in Patients with Lung Cancer Ended recruitment
  2024-516532-97-00 9 2020-03-26 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended recruitment
  2023-506782-56-00 5 2020-03-10 RET-Mutant Medullary Thyroid Cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer Ended recruitment
  2024-515560-30-00 7 2020-03-05 Advanced-stage, relapsed/refractory cancer
• A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9) Ended recruitment
  2023-507060-39-00 3 2020-03-04 Multiple Myeloma
• A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subj … Ended recruitment
  2023-503468-17-00 3 2020-03-02 Multiple myeloma
• Parent and/or Legal Guardian ICF and Adult patient ICF: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study wi … Ended recruitment
  2022-501012-34-00 5 2020-02-27 Pulmonary Arterial Hypertension
• IMMUWHY Ended recruitment
  2023-508314-42-00 4 2020-02-27 Advanced stage intrahepatic biliary tract cancer (BTC)
• A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431) Ended recruitment
  2023-506783-14-00 5 2020-02-24 Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended recruitment
  2024-511653-22-00 5 2020-02-12 Cutaneous Squamous Cell Carcinoma (CSCC)
• A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral trea … Ended recruitment
  2024-511940-20-00 5 2020-02-05 Parkinson's disease
• Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera … Ended recruitment
  2022-501973-37-00 5 2020-01-30 Endometrial cancer
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemop … Ended recruitment
  2022-502844-11-00 5 2020-01-29 severe to moderately severe hemophilia B (FIX:C ≤ 2%)
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended recruitment
  2023-509908-15-00 10 2020-01-20 Mantle Cell Lymphoma
• An exploratory, multicenter, randomized, open-label with blind evaluation, active controlled study to evaluate the safety and efficacy of Ke … Ended recruitment
  2024-515667-60-00 4 2020-01-14 Actinic keratosis
• Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer Ended recruitment
  2023-503831-17-00 4 2019-12-23 The treatment of participants with HRRm and/or HRD-positive cancer

Showing 2,353–2,376 of 3,391 trials